Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study.

被引：0
|
作者：
Cohen, Y
Shulman, K
Idelevich, E
Ben-Shachar, M
Honnigman, J
Haiat, H
Zidan, J
Hubert, A
Kuten, A
Beny, A
机构：
[1] Soroka Med Ctr, Beer Sheva, Israel
[2] Rambam Med Ctr, Haifa, Israel
[3] Kaplan Med Ctr, Rehovot, Israel
[4] Nahariya Med Ctr, Nahariyya, Israel
[5] HaEmek Med Ctr, Afula, Israel
[6] Wolfson Med Ctr, Holon, Israel
[7] Ziv Med Ctr, Sefad, Israel
[8] Hadassah Med Ctr, IL-91120 Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3742
引用
收藏
页码：304S / 304S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [22] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    Feliu, J
    Vicent, JM
    García-Girón, C
    Constela, M
    Fonseca, E
    Aparicio, J
    Lomas, M
    Antón-Aparicio, L
    Dorta, FJ
    González-Barón, M
    BRITISH JOURNAL OF CANCER, 2004, 91 (10) : 1758 - 1762
  • [23] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    J Feliu
    J M Vicent
    C García-Girón
    M Constela
    E Fonseca
    J Aparicio
    M Lomas
    L Antón-Aparicio
    F J Dorta
    M González-Barón
    British Journal of Cancer, 2004, 91 : 1758 - 1762
  • [24] Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer - A multicenter phase II study
    Vamvakas, L
    Kakolyris, S
    Kouroussis, C
    Kandilis, K
    Mavroudis, D
    Ziras, N
    Androulakis, N
    Kalbakis, K
    Sarra, E
    Souglakos, J
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 65 - 70
  • [25] Phase II study of irinotecan (CPT-11) in patients with 5-Fluorouracil-refractory metastatic colorectal carcinoma - An Asian experience
    Ang, PCS
    Koo, WH
    Au, E
    Ang, PT
    Khoo, KS
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [26] A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer
    Toh, U.
    Iwakuma, N.
    Otsuka, H.
    Takenaka, M.
    Ogo, E.
    Fujii, T.
    Tanaka, M.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)
    Sumii, Toshihiko
    Fujimori, Nao
    Funakoshi, Akihiro
    PANCREAS, 2008, 37 (01) : 112 - 112
  • [28] Phase I trial of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC).
    Gravalos, C
    Garcia-Alfonso, P
    Castellanos, D
    Martin, B
    Perez-Manga, G
    Cortes-Funes, H
    Gonzalez-Lama, J
    Paz-Ares, L
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 46
  • [29] Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma
    Firvida, JL
    Irigoyen, A
    Vázquez-Estévez, S
    Diz, P
    Constenla, M
    Casal-Rubio, J
    Valladares-Ayerbes, M
    Castellanos, J
    Rodríguez, R
    Balcells, M
    CANCER, 2001, 91 (04) : 704 - 711
  • [30] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer.
    Sugiyama, T
    Noda, K
    Yakushiji, M
    Kamura, T
    ANNALS OF ONCOLOGY, 2000, 11 : 86 - 86
12345